232 related articles for article (PubMed ID: 34442029)
1. Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3.
Putowski M; Giannopoulos K
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34442029
[TBL] [Abstract][Full Text] [Related]
2. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
3. NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia.
Maleki Y; Alahbakhshi Z; Heidari Z; Moradi MT; Rahimi Z; Yari K; Rahimi Z; Aznab M; Ahmadi-Khajevand M; Bahremand F
Oncol Lett; 2019 Apr; 17(4):4016-4023. PubMed ID: 30930998
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
6. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
7. The spectrum of genetic defects in chronic lymphocytic leukemia.
Rossi D; Fangazio M; Gaidano G
Mediterr J Hematol Infect Dis; 2012; 4(1):e2012076. PubMed ID: 23205264
[TBL] [Abstract][Full Text] [Related]
8. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.
Quijada-Álamo M; Hernández-Sánchez M; Robledo C; Hernández-Sánchez JM; Benito R; Montaño A; Rodríguez-Vicente AE; Quwaider D; Martín AÁ; García-Álvarez M; Vidal-Manceñido MJ; Ferrer-Garrido G; Delgado-Beltrán MP; Galende J; Rodríguez JN; Martín-Núñez G; Alonso JM; García de Coca A; Queizán JA; Sierra M; Aguilar C; Kohlmann A; Hernández JÁ; González M; Hernández-Rivas JM
J Hematol Oncol; 2017 Apr; 10(1):83. PubMed ID: 28399885
[TBL] [Abstract][Full Text] [Related]
10. New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.
Tripathi R; Lee-Verges E; Higashi M; Gimenez N; Rosich L; Lopez-Guerra M; Colomer D
Expert Opin Drug Discov; 2017 Oct; 12(10):1041-1052. PubMed ID: 28776453
[TBL] [Abstract][Full Text] [Related]
11. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
12. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
13. Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia.
Zakrzewska E; Pirog M; Purkot J; Giannopoulos K
Folia Histochem Cytobiol; 2017; 55(3):95-106. PubMed ID: 28994094
[TBL] [Abstract][Full Text] [Related]
14. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
Hu B; Patel KP; Chen HC; Wang X; Wang F; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating MJ; Wierda WG
Br J Haematol; 2019 Jun; 185(5):852-864. PubMed ID: 30924136
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.
Shuai W; Lin P; Strati P; Patel KP; Routbort MJ; Hu S; Wei P; Khoury JD; You MJ; Loghavi S; Tang Z; Fang H; Thakral B; Medeiros LJ; Wang W
Blood Cancer J; 2020 Aug; 10(8):86. PubMed ID: 32848129
[TBL] [Abstract][Full Text] [Related]
17. Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond.
Pozzo F; Bittolo T; Tissino E; Zucchetto A; Bomben R; Polcik L; Dannewitz Prosseda S; Hartmann TN; Gattei V
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740661
[TBL] [Abstract][Full Text] [Related]
18. BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.
Alhourani E; Othman MA; Melo JB; Carreira IM; Grygalewicz B; Vujić D; Zecević Z; Joksić G; Glaser A; Pohle B; Schlie C; Hauke S; Liehr T
Oncol Lett; 2016 May; 11(5):3240-3246. PubMed ID: 27123097
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
[TBL] [Abstract][Full Text] [Related]
20. The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1.
Rossi D; Rasi S; Spina V; Bruscaggin A; Monti S; Cresta S; Famà R; Deambrogi C; Greco M; Fangazio M; Ciardullo C; Piranda D; Casaluci GM; Messina M; Giudice ID; Chiaretti S; Marinelli M; Guarini A; Foà R; Gaidano G
Leuk Suppl; 2012 Aug; 1(Suppl 2):S26-8. PubMed ID: 27175239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
